BioXcel Therapeutics 경영진
경영진 기준 점검 3/4
BioXcel Therapeutics CEO는 Vimal Mehta, Apr2017 에 임명되었습니다 의 임기는 9.08 년입니다. 총 연간 보상은 $971.60K, 72.7% 급여 및 27.3% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $23.31K 가치에 해당하는 회사 주식의 0.079% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 5.3 년과 7.8 년입니다.
핵심 정보
Vimal Mehta
최고경영자
US$971.6k
총 보수
| CEO 급여 비율 | 72.72% |
| CEO 재임 기간 | 9.1yrs |
| CEO 지분 보유율 | 0.08% |
| 경영진 평균 재임 기간 | 5.3yrs |
| 이사회 평균 재임 기간 | 7.8yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • Apr 27
BTAI: At Home Agitation Opportunity Will Drive Future Upside Despite Dilution
Analysts have reset BioXcel Therapeutics' blended price target closer to $6, reflecting recent equity dilution while still pointing to what they view as attractive upside from the company's differentiated at home agitation franchise and expanding BXCL501 neuropsychiatry opportunities. Analyst Commentary Recent Street commentary on BioXcel Therapeutics centers on how to balance dilution driven pressure on the share price with what analysts see as meaningful potential around the BXCL501 franchise and the broader neuropsychiatry pipeline.내러티브 업데이트 • Apr 12
BTAI: At Home Agitation Franchise Will Drive Future Repricing Despite Dilution
Narrative Update The analyst fair value estimate for BioXcel Therapeutics has been adjusted slightly to $14.00 from $14.25, as analysts weigh the recent equity dilution against ongoing views that BXCL501's at-home agitation use and broader neuropsychiatry potential support a higher upside than current trading levels suggest. Analyst Commentary Recent Street research highlights a split view on BioXcel Therapeutics, with some analysts focused on the long-term potential of BXCL501 and others more focused on balance sheet pressure from equity issuance.내러티브 업데이트 • Mar 27
BTAI: At Home Agitation Expansion Will Drive Repricing Despite Dilution Concerns
Analysts now set an updated $14.25 price target for BioXcel Therapeutics, refining their outlook as they weigh enthusiasm around the at-home agitation franchise and expanding BXCL501 options against recent and expected equity dilution. Analyst Commentary Recent Street research reflects a split view on BioXcel Therapeutics, with some analysts emphasizing upside tied to the at-home agitation portfolio and others focusing more on the impact of equity dilution on upside potential.내러티브 업데이트 • Mar 12
BTAI: At Home Agitation sNDA Will Drive Repricing Despite Equity Dilution Concerns
Analysts have trimmed their fair value estimate for BioXcel Therapeutics from $15.25 to $14.25, reflecting a lower price target after recent Street research highlighted equity dilution as a key concern. Analyst Commentary Bullish Takeaways Bullish analysts still see upside potential even after the price target adjustment to US$6, suggesting they believe current valuation already reflects a good portion of the equity dilution risk.내러티브 업데이트 • Feb 25
BTAI: At Home Agitation sNDA And Planning Will Drive Repricing Potential
Analysts kept their $15.25 price target for BioXcel Therapeutics unchanged, citing relatively steady modeled fair value, a similar discount rate and revenue outlook, and only modest tweaks to profit margin and future P/E assumptions. What's in the News Completed an updated market opportunity assessment for IGALMI for acute agitation in bipolar disorder or schizophrenia in the at home setting, using insights from the SERENITY At Home study to guide launch planning.내러티브 업데이트 • Feb 10
BTAI: At Home Agitation Use Expansion Will Drive Repricing Potential
Analysts now see fair value for BioXcel Therapeutics at US$15.25, down from US$16.75. This reflects updated assumptions for growth, profitability and a higher future P/E multiple in their models.내러티브 업데이트 • Jan 27
BTAI: At Home Agitation Approval Effort Will Drive Repricing Potential
Analysts have revised their price target for BioXcel Therapeutics to US$16.75, with the change largely tied to updated assumptions for the discount rate, profit margin outlook, and a slightly lower future P/E multiple. What's in the News Submitted a supplemental New Drug Application (sNDA) to the U.S. FDA for IGALMI for at home treatment of agitation tied to bipolar disorders or schizophrenia, aiming to expand use beyond healthcare provider supervised settings where there are currently no FDA approved options (Key Developments).내러티브 업데이트 • Jan 10
BTAI: At Home Agitation sNDA And Safety Data Will Drive Repricing
Analysts have modestly reset their price target for BioXcel Therapeutics to US$16.75. This reflects updated assumptions around discount rate, profit margin, and future P/E that keep their fair value view broadly unchanged.내러티브 업데이트 • Dec 17
BTAI: At Home Agitation Approval Pathway Will Drive Bullish Repricing
Narrative Update on BioXcel Therapeutics Analysts have modestly lifted their price target on BioXcel Therapeutics, citing a reaffirmed fair value estimate near $16.75 per share, supported by stable long term growth and profitability assumptions, despite a slightly higher discount rate and modestly richer projected valuation multiples. What's in the News Shareholders are scheduled to vote at the December 12, 2025 AGM on an amendment to the certificate of incorporation that would enable a reverse stock split, which may reflect efforts to maintain listing compliance and improve share price optics (company filing).내러티브 업데이트 • Dec 03
BTAI: Phase 3 At Home Agitation Data Will Drive Bullish Repricing
Analysts have raised their price target on BioXcel Therapeutics to $4 from $2, citing stronger long term risk adjusted sales potential for BXCL501 supported by positive Phase 3 SERENITY At Home data, while still flagging financing uncertainty. Analyst Commentary Analysts updating their models following the SERENITY At Home readout are highlighting both improved long term revenue potential and persistent execution risks that temper the valuation upside.내러티브 업데이트 • Nov 19
BTAI: Strong Phase 3 Study Results Will Drive Further Market Momentum
Analysts have lowered their fair value estimate for BioXcel Therapeutics from $23.75 to $16.75 per share, citing improved long-term revenue projections and profit margins. This outlook is balanced by ongoing uncertainties related to the company’s financing strategy.내러티브 업데이트 • Nov 04
BTAI: Upcoming Regulatory Milestones Will Drive Momentum Following Key Phase 3 Success
Analysts have increased their fair value price target for BioXcel Therapeutics from $19 to $23.75, citing improved revenue growth expectations, a higher profit margin forecast, and optimism following positive BXCL501 study results as well as expanded indications. Analyst Commentary Recent analyst updates reflect a mix of optimism and ongoing caution surrounding BioXcel Therapeutics following positive developments for BXCL501 and improving financial projections.
새로운 내러티브 • Apr 17
BXCL501 And SERENITY Trials Will Unlock New Treatment Horizons
Advancing Phase III trials and successful SERENITY outcomes could expand market access and boost revenue through FDA approvals and new partnerships.분석 기사 • Jun 04
Shareholders May Be More Conservative With BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) CEO Compensation For Now
Key Insights BioXcel Therapeutics will host its Annual General Meeting on 10th of June CEO Vimal Mehta's total...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$75m |
| Dec 31 2025 | US$972k | US$707k | -US$70m |
| Sep 30 2025 | n/a | n/a | -US$68m |
| Jun 30 2025 | n/a | n/a | -US$51m |
| Mar 31 2025 | n/a | n/a | -US$40m |
| Dec 31 2024 | US$1m | US$1m | -US$60m |
| Sep 30 2024 | n/a | n/a | -US$71m |
| Jun 30 2024 | n/a | n/a | -US$108m |
| Mar 31 2024 | n/a | n/a | -US$153m |
| Dec 31 2023 | US$5m | US$1m | -US$179m |
| Sep 30 2023 | n/a | n/a | -US$212m |
| Jun 30 2023 | n/a | n/a | -US$203m |
| Mar 31 2023 | n/a | n/a | -US$187m |
| Dec 31 2022 | US$5m | US$944k | -US$166m |
| Sep 30 2022 | n/a | n/a | -US$137m |
| Jun 30 2022 | n/a | n/a | -US$122m |
| Mar 31 2022 | n/a | n/a | -US$112m |
| Dec 31 2021 | US$9m | US$917k | -US$107m |
| Sep 30 2021 | n/a | n/a | -US$102m |
| Jun 30 2021 | n/a | n/a | -US$100m |
| Mar 31 2021 | n/a | n/a | -US$94m |
| Dec 31 2020 | US$10m | US$890k | -US$82m |
| Sep 30 2020 | n/a | n/a | -US$69m |
| Jun 30 2020 | n/a | n/a | -US$54m |
| Mar 31 2020 | n/a | n/a | -US$41m |
| Dec 31 2019 | US$2m | US$459k | -US$33m |
보상 대 시장: Vimal의 총 보수(USD971.60K)는 US 시장에서 비슷한 규모 기업의 평균(USD649.34K)보다 높습니다.
보상과 수익: Vimal의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Vimal Mehta (63 yo)
9.1yrs
재임 기간
US$971,598
보수
Dr. Vimal D. Mehta, Ph D., is Co-Founder of BioXcel Corporation and following its inception in 2005, has served as its Chairman and Chief Executive Officer. Dr. Mehta served as a Director at Invea Therapeu...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Founder | 9.1yrs | US$971.60k | 0.079% $ 23.3k | |
| Senior VP & CFO | 8.6yrs | US$394.65k | 0.058% $ 17.1k | |
| Senior VP | 5.3yrs | US$432.58k | 0.059% $ 17.3k | |
| Executive VP & Chief Scientific Officer | 2.4yrs | US$1.15m | 0.057% $ 16.9k | |
| Acting Chief Commercial Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Vice President of Clinical Development | no data | 데이터 없음 | 데이터 없음 |
5.3yrs
평균 재임 기간
63yo
평균 나이
경험이 풍부한 관리: BTAI의 경영진은 노련하고 경험이 풍부합니다(평균 재임 5.3 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Founder | 9.1yrs | US$971.60k | 0.079% $ 23.3k | |
| Member of Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Chairman & Lead Director | 9.1yrs | US$130.00k | 0.043% $ 12.7k | |
| Member of Clinical Advisory Board | 7.8yrs | 데이터 없음 | 데이터 없음 | |
| Member of Clinical Advisory Board | 7.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Clinical Advisory Board | 7.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Clinical Advisory Board | 7.8yrs | 데이터 없음 | 데이터 없음 | |
| Member of Clinical Advisory Board | 7.8yrs | 데이터 없음 | 데이터 없음 | |
| Member of Clinical Advisory Board | 7.3yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 8.7yrs | US$92.50k | 0% $ 0 | |
| Member of Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Clinical Advisory Board | 7.8yrs | 데이터 없음 | 데이터 없음 |
7.8yrs
평균 재임 기간
63yo
평균 나이
경험이 풍부한 이사회: BTAI의 이사회는 경험이 있음으로 간주됩니다(평균 재임 7.8 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/21 07:25 |
| 종가 | 2026/05/21 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
BioXcel Therapeutics, Inc.는 10명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Anita Dushyanth | Berenberg |
| Guyn Kim | BMO Capital Markets Equity Research |
| Alec Stranahan | BofA Global Research |